ADVFN Logo ADVFN

We could not find any results for:
Make sure your spelling is correct or try broadening your search.

Trending Now

Toplists

It looks like you aren't logged in.
Click the button below to log in and view your recent history.

Sign Up

Already a member? Sign in

Top Brokers

More Brokers

Market Data
News
Trading Tools
Markets
Discover

Hot Features

Follow Feed

Connect with traders and investors in our Follow Feed community.

Options Flow

Explore comprehensive options data and use advanced filters with Options Flow.

Monitor

Organize and monitor your stock and asset watchlist with Monitor.
Sign In Premium IconPremium Help Menu
FTSE 100
8,245.37
-0.48%
Dow Jones
38,798.99
-0.22%
Gold vs US Dollar
2,293.845
0.00%
Brent Oil
79.395
0.00%
Bitcoin
69,345.54
0.02%
Pepperstone
Advertisement
Registration Strip Icon for alerts Register for real-time alerts, custom portfolio, and market movers
Get Started
  1. Home
  2. Investing
  3. Stocks
  4. USA
  5. NASDAQ

  6. ARS Pharmaceuticals Inc (SPRY) Share Price

SPRY ARS Pharmaceuticals Inc

8.81
-0.01 (-0.11%)
08 Jun 2024 - Closed
Delayed by 15 minutes
 Name  Symbol  Market  Type  ISIN  Description 
 ARS Pharmaceuticals Inc NASDAQ:SPRY NASDAQ Common Stock  
     Change  % Chg  Cur  Bid  Offer  High  Low  Open  Volume  Chg Time
Upgrade Icon
 		 RN  NRN 
   -0.01 -0.11 8.81 8.60 9.27 8.90 8.68 8.74 308,762 00:00:00   
 Type  Size  Price  Time  Units 
 9 30 8.71 23:43:34 USD
 
Pre-Market and After-Hours
Recent News
DateTimeSource
HeadlineMore SPRY News
17/05/202400:52EDGAR2Form 4 - Statement of changes in beneficial ownership of securities
10/05/202412:01EDGAR2Form 8-K - Current report
09/05/202423:59EDGAR2Form 4 - Statement of changes in beneficial ownership of securities
09/05/202421:08EDGAR2Form 8-K - Current report
09/05/202421:05GLOBEARS Pharmaceuticals Highlights neffy Regulatory Progress and Reports First Quarter 2024 Financial Results
30/04/202414:01GLOBEARS Pharmaceuticals Submits Response for neffy® (epinephrine nasal spray) Marketing Authorization Application to EMA’s CHMP and Enters License Agreement with CSL Seqirus for Commercialization of neffy in Australia and New Zealand
03/04/202414:01GLOBEARS Pharmaceuticals Submits Response to FDA Complete Response Letter for neffy® (Epinephrine Nasal Spray)
Period
Draw mode
Data Downloads for SPRY

Export historical price information open, high, low, close, volume (OHLCV) to Excel

Intraday price data (2 weeks, 1 minute bars)


Loading Follow Feed...

Latest ARS Pharmaceuticals Inc Articles